Cardiac Safety and Toxicity Service

Your choice for preclinical high throughput testing of human iPSC-derived cardiomyocyte contractility!

contractility service anchor

Our cardiac contractility service based on the FLEXcyte 96 platform is an end-to-end safety, toxicity and efficacy testing service with your drug candidate(s). We plan, prepare and conduct your contractility study for you!

Predictive Cell Model on a Higher Throughput System

HiPSC-derived cardiomyoctes are currently used in a variety of assays to improve cardiotoxicity guidelines in a Cipa (Comprehensive in vitro proarrhythmia assay) conform manner. We have validated a broad range of commercially available and Cipa accepted human iPSC-derived cardiomyocytes as most predictive cell model for the FLEXcyte 96 Service – a cardiac contractility assay on a higher throughput 96 well plate. We also welcome your in-house hiPSC cardiomyocytes to test and characterize.

Mature Cardiac Phenotype for Reliable Adult-Like Drug Responses

example data anchor

Drug induced adult-like responses of human iPSC-derived cardiomyocytes usually fail due to the juvenile phenotype of the cells. The flexible membranes of the FLEXcyte 96 plates form a natural biohybrid layer with the cells and provide a unique and necessary auxotonic environment in vitro to promote cell maturation. Mature cardiomyocyte responses on FLEXcyte 96 plates with commercially available human iPSC-derived cardiomyocytes can be detected upon treatment with positive inotropic compounds like isoproterenol and S-Bay K8644.

Acute & Chronic Testing of Your Drug Candidates

Dependend on the biological mechanism of your drug candidates, acute or chronic assessment of cardiac contractility may be necessary. The FLexcyte 96 service provides acute and chronic measurements, conducted from minutes up to one week after compound addition. Personalized settings can be tailored to your needs.

Tailored Study Report Covering All Parameters

The FLEXcyte technology delivers a comprehensive set of parameters measured on the contractile behaviour of cardiomyocytes. Parameters measured are Beat Rate, Beat Duration, Amplitude, Upstroke and Downstroke Velocity, Upstroke and Downstroke AUC as well as Arrhythmic Events. Our experts will deliver a full study report containing the essential study parameters and results of your drug candidates to evaluate their preclinical cardiac risk potential.

Dowload our FLEXcyte 96 service flyer here: FLEXcyte 96 - Safety and Toxicity Service Flyer

cell line characterization anchor

Cell Line Caracterization

News